IQVIA Holdings Inc.
IQVIA Holdings Inc.
Your view on IQV
Overview
What the company does, where it operates, and who runs it.
About IQVIA Holdings Inc.
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Ari Bousbib
- Headquarters
- 4820 Emperor boulevard, Durham, NC, US
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Ari Bousbib
- Headquarters
- 4820 Emperor boulevard, Durham, NC, US
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.
This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level.
The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services.
The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies.
The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Stock Data
Price chart, volume, and trading data.
What moved it
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for IQVIA Holdings Inc. from FRC's valuation model, read against the market price. IQV last traded at $264.73, 31.8× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for IQVIA Holdings Inc.. Starting points for IQVIA Holdings Inc.: P/E 31.8, EPS $8.46, beta 1.16 — an Medical - Diagnostics & Research name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for IQVIA Holdings Inc.. IQVIA Holdings Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for IQVIA Holdings Inc.. Trailing twelve-month EPS for IQVIA Holdings Inc. stands at $8.46. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$283.15
average of 13 firms, last 12 months
Analyst Ratings
- Strong Buy0
- Buy12
- Hold2
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $3.58 | $3.16 | $12.96 | $14.16 |
| Low estimate | $3.54 | $3.13 | $12.94 | $13.49 |
| High estimate | $3.67 | $3.21 | $13.00 | $15.22 |
| No. of analysts | 11 | 8 | 13 | 13 |
| Year-ago EPS | $3.42 | $2.90 | $7.84 | — |
| Growth | +4.8% | +9.1% | +65.3% | — |
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $4.53B | $4.45B | $17.48B | $18.55B |
| Low estimate | $4.49B | $4.40B | $17.44B | $18.32B |
| High estimate | $4.58B | $4.51B | $17.54B | $19.07B |
| No. of analysts | 10 | 7 | 14 | 14 |
| Year-ago revenue | $4.36B | $4.15B | $16.31B | — |
| Growth | +3.7% | +7.2% | +7.2% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga, Pulse 2.0; as of Nov 18, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for IQVIA Holdings Inc.. IQVIA Holdings Inc. has reported as a listed company since 2013. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- ALBBYAlibaba Health Information Technology LimitedMedical - Healthcare Information Services$12.4B
- CERTCertara, Inc.Medical - Healthcare Information Services$1.7B
- CRLCharles River Laboratories International, Inc.Medical - Diagnostics & Research$16.1B
- FTREFortrea Holdings Inc.Biotechnology$1.9B
- HCATHealth Catalyst, Inc.Medical - Healthcare Information Services$105M
- ICLRICON Public Limited CompanyMedical - Diagnostics & Research$14.3B
- MEDPMedpace Holdings, Inc.Medical - Diagnostics & Research$18.1B
- MTHRFM3, Inc.Medical - Healthcare Information Services$7.7B
More Medical - Diagnostics & Research companies
- TMO.NEThermo Fisher Scientific Inc.NEO
- TOMDFTodos Medical Ltd.OTC$14,081
- TTOOT2 Biosystems, Inc.OTC$11,218
- TWSTTwist Bioscience CorporationNASDAQ$6.9B
- VCYTVeracyte, Inc.NASDAQ$1.9B
- VIMGFVimian Group AB (publ)OTC$1.5B
- VRCDFVerici Dx plcOTC$5M
- WATWaters CorporationNYSE$44.6B
- WGSGeneDx Holdings Corp.NASDAQ$1.5B
- WUXAYWuXi AppTec Co., Ltd.OTC$45.6B
- WUXIFWuXi AppTec Co., Ltd.OTC$39.8B
- XGNExagen Inc.NASDAQ$96M
ETFs holding IQVIA Holdings Inc.
% of the fund
- VOOVanguard S&P 500 ETF$1.0T in assets0.07%
- VTIVanguard Total Stock Market ETF$689.2B in assets0.06%
- VOVanguard Mid-Cap ETF$103.4B in assets0.42%
- IVViShares Core SP 500 ETF$852.9B in assets0.07%
- SPYState Street SPDR S&P 500 ETF Trust$818.5B in assets0.07%
- BBHVanEck Biotech ETF$536M in assets4.21%
- TAOZThornburg American Opportunities Fund$488M in assets3.59%
- OAKMOakmark U.S. Large Cap ETF$1.2B in assets2.68%
Largest holders first, then the funds most concentrated in IQV.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold IQVIA Holdings Inc., and how their positions are changing. At a $43.63B market value, institutional positions materially move IQVIA Holdings Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by IQVIA Holdings Inc. executives and directors. Shares of IQVIA Holdings Inc. have traded between $134.65 and $228.12 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
About this section
U.S. Senate disclosures naming IQVIA Holdings Inc.. IQVIA Holdings Inc. is a $43.63B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
About this section
U.S. House of Representatives disclosures naming IQVIA Holdings Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for IQVIA Holdings Inc.. Coverage tracks IQVIA Holdings Inc. within Medical - Diagnostics & Research (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of IQVIA Holdings Inc.